Laurus Labs Limited
National Stock Exchange of IndiaTotal Valuation
Laurus Labs Limited carries a market capitalization of 752.72B, placing it among publicly traded companies globally. Its enterprise value stands at 390.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 752.72B |
| Enterprise Value | 390.40B |
Valuation Ratios
Laurus Labs Limited trades at a trailing price-to-earnings ratio of 76.73.
| PE Ratio | 76.73 |
| PS Ratio | 6.64 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Laurus Labs Limited trades at an EV/EBITDA multiple of 47.30 and an EV/FCF ratio of 256.24. The EV/Sales ratio of 6.64 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 47.30 provides insight into valuation relative to core operating earnings.
| EV / Sales | 6.64 |
| EV / EBITDA | 47.30 |
| EV / EBIT | 47.30 |
| EV / FCF | 256.24 |
Financial Position
Laurus Labs Limited maintains a current ratio of 2.41, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 127.35, indicating elevated leverage, while an interest coverage ratio of 3.95 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 2.41 |
| Quick Ratio | 0.06 |
| Debt / Equity | 127.35 |
| Debt / EBITDA | N/A |
| Interest Coverage | 3.95 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 7.32 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Laurus Labs Limited has paid 1.87B in income taxes, reflecting an effective tax rate of 27.07.
| Income Tax | 1.87B |
| Effective Tax Rate | 27.07 |
Stock Price Statistics
Laurus Labs Limited's stock has gained approximately 125.03228% over the past 52 weeks. The 50-day moving average sits at 1,179.19, while the 200-day moving average is 1,030.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | 125.03228% |
| 50-Day Moving Average | 1,179.19 |
| 200-Day Moving Average | 1,030.95 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Laurus Labs Limited generated 58.83B in revenue and converted that into 5.09B in net income, yielding earnings per share of 9.42. EBITDA reached 8.25B, while operating income came in at 8.25B.
| Revenue | 58.83B |
| Gross Profit | 32.43B |
| Operating Income | 8.25B |
| Pretax Income | 6.90B |
| Net Income | 5.09B |
| EBITDA | 8.25B |
| EBIT | 8.25B |
| Earnings Per Share (EPS) | 9.42 |
Margins
Laurus Labs Limited operates with a gross margin of 55.12, reflecting its pricing power and cost economics. The operating margin of 14.03 and net profit margin of 8.65 provide insight into operational efficiency.
| Gross Margin | 55.12 |
| Operating Margin | 14.03 |
| Pretax Margin | 11.73 |
| Profit Margin | 8.65 |
| EBITDA Margin | 14.03 |
Stock Splits
Laurus Labs Limited's most recent stock split took place on September 29, 2020 with a 1:5 split ratio.
| Last Split Date | 9/29/2020 |
| Split Ratio | 1:5 |
Scores
Laurus Labs Limited posts an Altman Z-Score of 5.58, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.58 |